Johnson & Johnson (JNJ) Expected to Report 21% Q4 Earnings Growth with $24.16B Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: seekingalpha
- Earnings Expectations: Johnson & Johnson is expected to report Q4 earnings of $2.47 per share and revenue of $24.16 billion on January 21, reflecting a 7.4% year-on-year growth, indicating strong performance in its core business.
- Sustained Growth Potential: Analysts project J&J will achieve over 5% sustained revenue growth through 2030, driven by mid-single-digit growth in Innovative Medicines and a MedTech business shifting towards higher-growth segments, enhancing market confidence.
- Future Sales Forecast: Analysts forecast J&J's sales to reach $99.5 billion by 2026, with EPS guidance of $11.50 aligning with Wall Street estimates, indicating robust growth potential in the coming years.
- Risk Warnings: Despite J&J's 100% track record of beating EPS and revenue estimates over the past two years, analysts caution that rising competition in the MedTech sector and sluggish revenue growth from new products may pose risks to the company's future performance.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 218.660
Low
190.00
Averages
218.50
High
240.00
Current: 218.660
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
